News articles about Momenta Pharmaceuticals (NASDAQ:MNTA) have been trending somewhat positive on Monday, according to Accern Sentiment. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Momenta Pharmaceuticals earned a news impact score of 0.22 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.6346576695871 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news headlines that may have impacted Accern Sentiment’s rankings:
A number of analysts have recently commented on MNTA shares. Zacks Investment Research downgraded Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, December 4th. Stifel Nicolaus restated a “hold” rating and issued a $18.00 target price on shares of Momenta Pharmaceuticals in a research note on Tuesday, January 30th. BidaskClub downgraded Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. Finally, Cowen set a $15.00 price target on Momenta Pharmaceuticals and gave the stock a “hold” rating in a report on Wednesday, November 1st. Two research analysts have rated the stock with a sell rating and ten have issued a hold rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $15.30.
Shares of Momenta Pharmaceuticals (NASDAQ MNTA) traded up $0.05 during trading on Monday, hitting $16.30. The company’s stock had a trading volume of 579,727 shares, compared to its average volume of 902,704. Momenta Pharmaceuticals has a fifty-two week low of $11.85 and a fifty-two week high of $19.55. The firm has a market capitalization of $1,250.00, a PE ratio of -20.38 and a beta of 1.80.
In other Momenta Pharmaceuticals news, Director Elizabeth Stoner sold 5,500 shares of the stock in a transaction that occurred on Wednesday, December 13th. The stock was sold at an average price of $13.10, for a total transaction of $72,050.00. Following the completion of the transaction, the director now owns 13,240 shares of the company’s stock, valued at $173,444. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Craig A. Wheeler sold 10,406 shares of the stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $15.89, for a total value of $165,351.34. Following the completion of the sale, the chief executive officer now directly owns 275,526 shares of the company’s stock, valued at approximately $4,378,108.14. The disclosure for this sale can be found here. Insiders have sold 77,354 shares of company stock valued at $1,170,153 in the last three months. Insiders own 4.40% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Momenta Pharmaceuticals (MNTA) Earning Somewhat Positive News Coverage, Report Finds” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/12/momenta-pharmaceuticals-mnta-getting-somewhat-favorable-media-coverage-report-shows.html.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.